The invention relates to novel substituted 8-sulfonyl-2,3,4,5-tetrahydro-1H-γ-carbolines of the general formula 1 and their pharmaceutically acceptable salt—ligands exhibiting biological activity simultaneously towards alpha-adrenoceptors, dopamine receptors, histamine receptors, imidazoline receptors, sigma receptors, norepinefrine receptors, serotonin receptors, to active components, pharmaceutical compositions, comprising as an active component novel ligands, to novel medicaments intended for treatment of conditions and diseases of central nervous system. In the general formula 1
R
1
represents a substituent selected from hydrogen, optionally substituted C
1
-C
3
alkyl or C
1
-C
4
alkyloxycarbonyl; R
2
represents a cyclic system substituent selected from hydrogen, optionally substituted C
1
-C
3
alkyl, optionally substituted C
2
-C
3
alkenyl or substituted sulfonyl; R
3
represents optionally substituted aryl or substituted amino group.
该发明涉及一种新型的取代的8-磺酰基-2,3,4,5-四
氢-1H-γ-咔啉的化合物,其一般式为1,以及它们的药用盐——
配体,同时对α-
肾上腺素受体、
多巴胺受体、
组胺受体、
咪唑啉受体、西格玛受体、
去甲肾上腺素受体、5-羟
色胺受体表现出
生物活性的
配体,以及作为活性成分的新型
配体组成的药物组合物,用于治疗中枢神经系统疾病和病症的新型药物。在一般式1中,R1代表从
氢、可选取代的C1-C3烷基或C1-C4烷
氧羰基中选择的取代基;R2代表从
氢、可选取代的C1-C3烷基、可选取代的C2-C3
烯基或取代的磺酰基中选择的环系统取代基;R3代表可选取代的芳基或取代的
氨基团。